Michael Maes
Maes Clinics @ TRIA
Piyavate Hospital 998 Rimklongsamsen Road
Bangkok
10310
Thailand
Name/email consistency: high
- Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression. Maes, M. Metab. Brain. Dis (2012)
- IgM-mediated autoimmune responses directed against anchorage epitopes are greater in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) than in major depression. Maes, M., Mihaylova, I., Kubera, M., Leunis, J.C., Twisk, F.N., Geffard, M. Metab. Brain. Dis (2012)
- New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Maes, M., Fišar, Z., Medina, M., Scapagnini, G., Nowak, G., Berk, M. Inflammopharmacology (2012)
- Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Maes, M., Galecki, P., Verkerk, R., Rief, W. Neuro Endocrinol. Lett. (2011)